Belgium· BE-AMP-SAM661548-00

Omvoh 300 mg

A mirikizumab product containing mirikizumab, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 13 of our 19 countries.

ATC L04AC24

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOmvoh 300 mgATCL04AC24REGISTER NO.BE-AMP-SAM661548-00PACKS LISTED4CHECKEDSeptember 26, 2026

Where it is registered

Mirikizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Mirikizumab · ATC L04AC24

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mirikizumab costs, country by country.

Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mirikizumab · price per daily dose (7.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$30.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Mirikizumab
Manufacturer
Eli Lilly Nederland
Country
Belgium (BE)
ATC code
L04AC24
ATC class
Mirikizumab
Defined daily dose
7.1 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 4

  • be_apb
    4830899
  • be_apb
    7740525
  • be_apb
    4962650
  • be_apb
    7747629

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mirikizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mirikizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Omvoh
  • Liechtenstein · Omvoh
  • Norway · Omvoh

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4fb7fbd0-f354-47a6-800b-2f0611d5265e
GET /v1/drugs/4fb7fbd0-f354-47a6-800b-2f0611d5265e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Omvoh 300 mg",
  "name_fr": "Omvoh 300 mg",
  "name_nl": "Omvoh 300 mg",
  "amp_code": "SAM661548-00",
  "strengths": [
    "20.0000",
    "20.0000",
    "20.0000",
    "60.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Mirikizumab",
    "Polysorbate 80",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Mirikizumab",
  "authorisation_numbers": [
    "EU/1/23/1736/001",
    "EU/1/23/1736/011"
  ]
}

See everything about mirikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.